Docking Methodologies and Recent Advances

Docking, a molecular modelling method, has wide applications in identification and optimization in modern drug discovery. This chapter addresses the recent advances in the docking methodologies like fragment docking, covalent docking, inverse docking, post processing, hybrid techniques, homology modeling etc. and its protocol like searching and scoring functions. Advances in scoring functions for e.g. consensus scoring, quantum mechanics methods, clustering and entropy based methods, fingerprinting, etc. are used to overcome the limitations of the commonly used force-field, empirical and knowledge based scoring functions. It will cover crucial necessities and different algorithms of docking and scoring. Further different aspects like protein flexibility, ligand sampling and flexibility, and the performance of scoring function will be discussed.

[1]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[2]  H. Wolfson,et al.  Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .

[3]  X. Zou,et al.  Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking , 2006, Proteins.

[4]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[5]  Martin Stahl,et al.  Scoring functions for protein-ligand interactions: a critical perspective. , 2004, Drug discovery today. Technologies.

[6]  Sheng-You Huang,et al.  Exploring the potential of global protein-protein docking: an overview and critical assessment of current programs for automatic ab initio docking. , 2015, Drug discovery today.

[7]  Thomas Stützle,et al.  PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design , 2006, ANTS Workshop.

[8]  Obdulia Rabal,et al.  APIF: A New Interaction Fingerprint Based on Atom Pairs and Its Application to Virtual Screening , 2009, J. Chem. Inf. Model..

[9]  Aldo Yair Tenorio-Barajas,et al.  Protein-Protein and Protein-Ligand Docking , 2013 .

[10]  X. Barril,et al.  Incorporating protein flexibility into docking and structure-based drug design , 2006, Expert opinion on drug discovery.

[11]  Abdelaziz Ghanemi.  Targeting G protein coupled receptor-related pathways as emerging molecular therapies , 2013, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[12]  Elizabeth Yuriev,et al.  Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.

[13]  Shuo Zhou,et al.  CovalentDock Cloud: a web server for automated covalent docking , 2013, Nucleic Acids Res..

[14]  Russell C. Eberhart,et al.  Recent advances in particle swarm , 2004, Proceedings of the 2004 Congress on Evolutionary Computation (IEEE Cat. No.04TH8753).

[15]  Rahul Agarwal,et al.  Role of Molecular Docking in Computer-Aided Drug Design and Development , 2016 .

[16]  A. Caflisch,et al.  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). , 2009, Journal of medicinal chemistry.

[17]  V. Vyas,et al.  Virtual Screening: A Fast Tool for Drug Design , 2008 .

[18]  Gregory McAllister,et al.  Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness. , 2011, Journal of medicinal chemistry.

[19]  Markus H. J. Seifert,et al.  Robust optimization of scoring functions for a target class , 2009, J. Comput. Aided Mol. Des..

[20]  Soumendranath Bhakat,et al.  Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls , 2015, Molecules.

[21]  Y. Kwan,et al.  Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors. , 2015, Methods.

[22]  Alexandre M. J. J. Bonvin,et al.  Pushing the limits of what is achievable in protein–DNA docking: benchmarking HADDOCK’s performance , 2010, Nucleic acids research.

[23]  Robert Powers,et al.  Application of NMR and molecular docking in structure-based drug discovery. , 2012, Topics in current chemistry.

[24]  Chung F Wong,et al.  Flexible ligand-flexible protein docking in protein kinase systems. , 2008, Biochimica et biophysica acta.

[25]  Chenglong Li,et al.  Novel Inhibitor Discovery through Virtual Screening against Multiple Protein Conformations Generated via Ligand-Directed Modeling: A Maternal Embryonic Leucine Zipper Kinase Example , 2012, J. Chem. Inf. Model..

[26]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[27]  Ahmad F. Eweas,et al.  Advances in molecular modeling and docking as a tool for modern drug discovery , 2014 .

[28]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[29]  B. McConkey,et al.  The performance of current methods in ligand-protein docking , 2002 .

[30]  Sangtae Kim,et al.  Position Specific Interaction Dependent Scoring Technique for Virtual Screening Based on Weighted Protein-Ligand Interaction Fingerprint Profiles , 2009, J. Chem. Inf. Model..

[31]  Claudio N. Cavasotto,et al.  The Challenge of Considering Receptor Flexibility in Ligand Docking and Virtual Screening , 2005 .

[32]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[33]  Walter Filgueira de Azevedo,et al.  Molecular docking algorithms. , 2008, Current drug targets.

[34]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[35]  Elizabeth Yuriev,et al.  Challenges and advances in computational docking: 2009 in review , 2011, Journal of molecular recognition : JMR.

[36]  P Chambon,et al.  Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Kumar Rakesh,et al.  MOLECULAR DOCKING: A REVIEW , 2011 .

[38]  António J. M. Ribeiro,et al.  Protein-ligand docking in the new millennium--a retrospective of 10 years in the field. , 2013, Current medicinal chemistry.

[39]  E. Lindahl,et al.  Functional Validation of Virtual Screening for Novel Agents with General Anesthetic Action at Ligand-Gated Ion Channels , 2013, Molecular Pharmacology.

[40]  William N. Setzer,et al.  In-silico Leishmania Target Selectivity of Antiparasitic Terpenoids , 2013, Molecules.

[41]  Ruben Abagyan,et al.  In silico discovery of novel Retinoic Acid Receptor agonist structures , 2001, BMC Structural Biology.

[42]  Xiaoqin Zou,et al.  Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. , 2010, Physical chemistry chemical physics : PCCP.

[43]  G. Jayson,et al.  ZD1839 (IRESSA™): a selective EGFR-TK inhibitor , 2002, Expert review of anticancer therapy.

[44]  Xiaoqin Zou,et al.  Challenges, Applications, and Recent Advances of Protein-Ligand Docking in Structure-Based Drug Design , 2014, Molecules.

[45]  Thierry Langer,et al.  Recent Advances in Docking and Scoring , 2005 .

[46]  Equal contributors , 2022 .

[47]  D. Bailey,et al.  High-throughput chemistry and structure-based design: survival of the smartest. , 2001, Drug discovery today.

[48]  Xiaoqin Zou,et al.  Advances and Challenges in Protein-Ligand Docking , 2010, International journal of molecular sciences.

[49]  Michal Brylinski,et al.  Comprehensive Structural and Functional Characterization of the Human Kinome by Protein Structure Modeling and Ligand Virtual Screening , 2010, J. Chem. Inf. Model..

[50]  Roy Bickerstaffe,et al.  Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis. , 2011, Journal of medicinal chemistry.

[51]  Rebecca C. Wade,et al.  Protein‐Protein Docking , 2001 .

[52]  H. Carlson.  Protein flexibility and drug design: how to hit a moving target. , 2002, Current opinion in chemical biology.

[53]  Denise Teotico Pohlhaus,et al.  In silico docking and scoring of fragments. , 2010, Drug discovery today. Technologies.

[54]  Piotr Paneth,et al.  Assessing Molecular Docking Tools for Relative Biological Activity Prediction: A Case Study of Triazole HIV-1 NNRTIs , 2013, J. Chem. Inf. Model..

[55]  Jonathan W. Essex,et al.  A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..

[56]  Sheng-You Huang,et al.  Search strategies and evaluation in protein-protein docking: principles, advances and challenges. , 2014, Drug discovery today.

[57]  Yu-chian Chen.  Beware of docking! , 2015, Trends in pharmacological sciences.

[58]  D. Fabbro.  25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations , 2015, Molecular Pharmacology.

[59]  R. Abagyan,et al.  Flexible ligand docking to multiple receptor conformations: a practical alternative. , 2008, Current opinion in structural biology.

[60]  Sandeep Jain,et al.  Study of binding of pyridoacridine alkaloids on topoisomerase II using in silico tools , 2013, Medicinal Chemistry Research.

[61]  Holger Gohlke,et al.  Steering Protein-Ligand Docking with Quantitative NMR Chemical Shift Perturbations , 2009, J. Chem. Inf. Model..

[62]  Oleksandr V. Buzko,et al.  Modified AutoDock for accurate docking of protein kinase inhibitors , 2002, J. Comput. Aided Mol. Des..

[63]  S. Singh,et al.  Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. , 2013, Journal of theoretical biology.

[64]  Annalisa Bordogna,et al.  New Aryl Hydrocarbon Receptor Homology Model Targeted To Improve Docking Reliability , 2011, J. Chem. Inf. Model..

[65]  P. Dean,et al.  Recent advances in structure-based rational drug design. , 2000, Current opinion in structural biology.

[66]  Maurizio Botta,et al.  Protein Kinases: Docking and Homology Modeling Reliability , 2010, J. Chem. Inf. Model..

[67]  Luhua Lai,et al.  Molecular Docking and Competitive Binding Study Discovered Different Binding Modes of Microsomal Prostaglandin E Synthase-1 Inhibitors , 2011, J. Chem. Inf. Model..

[68]  M. Taha,et al.  In Silico Screening for Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors Using Physicochemical Filters and High‐Throughput Docking Followed by In Vitro Evaluation , 2009, Chemical biology & drug design.

[69]  Márton Vass,et al.  Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. , 2014, European journal of medicinal chemistry.

[70]  A Srinivas Reddy,et al.  Virtual screening in drug discovery -- a computational perspective. , 2007, Current protein & peptide science.

[71]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[72]  Xiaoqin Zou,et al.  Efficient molecular docking of NMR structures: Application to HIV‐1 protease , 2006, Protein science : a publication of the Protein Society.

[73]  Maurizio Fermeglia,et al.  Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor. , 2011, ACS medicinal chemistry letters.

[74]  E. Jaeger,et al.  Docking: successes and challenges. , 2005, Current pharmaceutical design.

[75]  Junhai Xiao,et al.  Novel Substituted Heteroaromatic Piperazine and Piperidine Derivatives as Inhibitors of Human Enterovirus 71 and Coxsackievirus A16 , 2013, Molecules.

[76]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Tingjun Hou,et al.  Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.

[78]  Somesh D. Sharma,et al.  Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.

[79]  Dario R Alessi,et al.  Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.

[80]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[81]  Alexander Wlodawer,et al.  Rational approach to AIDS drug design through structural biology. , 2002, Annual review of medicine.

[82]  Ilizaliturri-Flores Ian,et al.  IDENTIFICATION OF PHARMACOLOGICAL TARGETS COMBINING DOCKING AND MOLECULAR DYNAMICS SIMULATIONS , 2013 .

[83]  Christofer S Tautermann,et al.  GPCR structures in drug design, emerging opportunities with new structures. , 2014, Bioorganic & medicinal chemistry letters.

[84]  Jacob D. Durrant,et al.  Computer-aided drug-discovery techniques that account for receptor flexibility. , 2010, Current opinion in pharmacology.

[85]  N. Jain,et al.  Estrogenic and Anti-Alzheimer’s studies of Zingiber officinalis as well as Amomum subulatum Roxb.: the success story of dry techniques , 2015, Medicinal Chemistry Research.

[86]  René Thomsen,et al.  Flexible ligand docking using evolutionary algorithms: investigating the effects of variation operators and local search hybrids. , 2003, Bio Systems.

[87]  Stephen H Hughes,et al.  Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues. , 2003, Journal of medicinal chemistry.

[88]  Jens Meiler,et al.  Assessment and Challenges of Ligand Docking into Comparative Models of G-Protein Coupled Receptors , 2013, PloS one.

[89]  J. Mccammon,et al.  Exploring the role of receptor flexibility in structure-based drug discovery. , 2014, Biophysical chemistry.

[90]  Aurélien Grosdidier,et al.  Blind docking of 260 protein–ligand complexes with EADock 2.0 , 2009, J. Comput. Chem..

[91]  Amedeo Caflisch,et al.  Quantum mechanical methods for drug design. , 2010, Current topics in medicinal chemistry.

[92]  Janine Smith,et al.  Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. , 2005, Clinical therapeutics.

[93]  Nasim Hasan Rama,et al.  Identification of novel urease inhibitors by high-throughput virtual and in vitro screening. , 2010, ACS medicinal chemistry letters.

[94]  H. Treutlein,et al.  Protein flexibility: multiple molecular dynamics simulations of insulin chain B. , 2006, Biophysical chemistry.

[95]  Haruki Nakamura,et al.  Selection of In Silico Drug Screening Results for G-Protein-Coupled Receptors by Using Universal Active Probes , 2011, J. Chem. Inf. Model..